Seeking Alpha

InterMune (ITMN -1.2%) slips a bit this morning after saying late yesterday that 2013 revenue...

InterMune (ITMN -1.2%) slips a bit this morning after saying late yesterday that 2013 revenue from sales of Esbriet will depend largely on the timing of its launch efforts in several European countries. The drug is designed for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease and is the only approved treatment worldwide.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)